Minimally Invasive Aortic Valve Surgery | Aortic Valve Overview | Aortic Stenosis | Transcatheter Aortic Valve Replacement | Aortic Facts | Aortic Valve Repair | Aortic Valve Bypass | The Ross Procedure | Aortic Valve Replacement | FAQ | Aortic Valve Surgery 101 | Patient Success Stories | Surgical Webcast | Clinical Trial for PARTNER II | PARTNER II Trial: Referring Physician Information
Courtesy of Edwards Lifesciences
The Heart Center at the University of Maryland is one of the first programs in the country to offer patients treatment with the first FDA-approved device for transcatheter aortic valve replacement (TAVR).
This minimally invasive approach to heart valve replacement is specifically for the treatment of patients with severe symptomatic native aortic valve stenosis who have been determined by a cardiac surgeon to be inoperable for open-chest aortic valve replacement, and whom meet other criteria to deem them eligible for this TAVR approach.
This transcatheter procedure enables the placement of a collapsible aortic heart valve into the body via a catheter-based approach, which allows the valve to be inserted via the femoral artery in the thigh. The valve is designed to replace a patient’s diseased native aortic valve without traditional open-heart surgery and while the heart continues to beat – removing the need for cardiopulmonary bypass.